ArticleVascular health and risk management2017

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Vybhav Jetty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.